Merit Financial Group LLC has expanded its holdings in Boston Scientific Corporation by 12% during the second quarter. According to an SEC filing, the firm added 14,508 shares to reach a total of 134,928 shares of the medical equipment giant.
Merit Financial Group LLC Acquires 14,508 Shares of Boston Scientific Corporation $BSX

Key Takeaways:
- Merit Financial Group LLC acquired an additional 14,508 shares of Boston Scientific
- This purchase reflects a 12.0% increase in Merit’s holdings
- Boston Scientific is a leading medical equipment provider listed on NYSE as BSX
- The information comes from the firm’s recent SEC filing
Overview of the Investment
Merit Financial Group LLC recently increased its stake in Boston Scientific Corporation, a major medical equipment provider listed on the New York Stock Exchange under the ticker BSX. In a move disclosed in its most recent filing with the Securities and Exchange Commission, the investment group boosted its holdings by 12.0% in the second quarter.
Filing Details
According to the SEC filing, Merit Financial Group LLC acquired an additional 14,508 shares, increasing its total ownership to 134,928 shares. The filing underscores the firm’s continued confidence in Boston Scientific’s performance in the medical equipment sector.
Focus on Boston Scientific
Boston Scientific is recognized for its range of medical devices and solutions. The company’s presence on the New York Stock Exchange signals a broad investor base, and Merit Financial Group’s decision to acquire more shares highlights the appeal of these products and services.
Significance for Merit Financial Group LLC
By adding to its position, Merit Financial Group LLC demonstrates a strategic approach aimed at strengthening its portfolio. While the filing offers no direct commentary on the rationale, the purchase aligns with ongoing interest in healthcare-related investments, given the sector’s long-term growth potential.
Looking Ahead
The second-quarter transaction positions Merit Financial Group LLC as a noteworthy shareholder in Boston Scientific. Although the filing does not detail any further plans, the 12.0% uplift in holdings may signal continued optimism in the trajectory of Boston Scientific and its role in the global medical equipment market.